Deep Dive: Thematics offer diversification but investors must consider bond sensitivity

‘Dedicated specialists’

James Baxter-Derrington
clock • 4 min read

Thematic funds offer an effective toolkit to diversify portfolios and gain access to “dedicated specialists” in a variety of intricate themes, but investors must be cognisant of the risks that come with the higher-duration equity funds’ sensitivity to real bond yields.

Speaking to Investment Week, Quilter WealthSelect manager Stuart Clark explained that thematic holdings act as diversifiers to traditional exposures, and their team utilises the funds to gain exposure to areas in which the "additional layer of specialist knowledge" is supportive of both stock selection and risk management. Clark cited natural resources as one example in which this specialist knowledge is beneficial: "Natural resource equities can be an area where generalist managers can struggle with assessing the quality of resources or the conflicting factors that can drive the underly...

To continue reading this article...

Join Investment Week for free

  • Unlimited access to real-time news, analysis and opinion from the investment industry, including the Sustainable Hub covering fund news from the ESG space
  • Get ahead of regulatory and technological changes affecting fund management
  • Important and breaking news stories selected by the editors delivered straight to your inbox each day
  • Weekly members-only newsletter with exclusive opinion pieces from leading industry experts
  • Be the first to hear about our extensive events schedule and awards programmes

Join now

 

Already an Investment Week
member?

Login

More on Specialist

Deep Dive: Thematics offer diversification but investors must consider bond sensitivity

Deep Dive: Thematics offer diversification but investors must consider bond sensitivity

‘Dedicated specialists’

James Baxter-Derrington
clock 06 April 2023 • 4 min read
European private equity yet to spend €270bn worth of capital

European private equity yet to spend €270bn worth of capital

Deployment of capital expected

Kathleen Gallagher
clock 04 January 2023 • 1 min read
Early-stage biopharma: An opportunity for strategic investment

Early-stage biopharma: An opportunity for strategic investment

Disproportionately smaller investment

Ali H. Munawar
clock 10 August 2022 • 4 min read
Trustpilot